Overcoming Challenges and Accelerating the Path to Patients: Part 1
Learn about how FUJIFILM Biotechnologies supports clients from early process development to commercial readiness in our recent webinar.
Efficient and Effective Delivery of AAV Therapies to Patients via Candidate Screening and Feasibility Studies
Navigate the current AAV manufacturing climate and consider the benefits of a modular approach.
Best of 2023: Highlights from our Lunch and Learn Series
This year, FUJIFILM Biotechnologies continued hosting our informative series of Lunch and Learns.
Drug Product Filling Line for Biologics and Viral Gene Therapy
Learn More about Drug Product Filling Line for Biologics and Viral Gene Therapy First Name(Required)Last Name(Required)Company Name(Required)Country(Required)United StatesUnited KingdomAfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua...
Our Formulation Development Approach
A molecule with great therapeutic potential is only as good as its formulation. At FUJIFILM Biotechnologies, our team start thinking...
FUJIFILM Biotechnologies Capacity Update October 2023: Cell & Gene
Lan Ly, PhD., Viral Gene Therapy Business Steering Group Lead and Sara Miller, Cell Therapy Business Steering Group Lead at...
Explore Gene Therapy Unlocked: Overcoming Challenges and Accelerating the Path to Patients
Steve Loftus explores the major challenges associated with the development of microbial fermentation processes, as well as how FUJIFILM Biotechnologies’s capabilities and expertise can help customers…
FUJIFILM Biotechnologies Capacity Update October 2023: Biologics
Michael Dunn, Vice President, Commercial Development and Cristina Brinkmann, Drug Product & Finished Goods Business Steering Group Lead, FUJIFILM Biotechnologies,...
Bioinformatics: A Vital Precursor to Successful Biomanufacturing
Monoclonal antibodies (mAbs) and novel antibodies can display good specificity and affinity for their targets, but their physical and chemical instability can have a detrimental…